McKinzie CJ - Search Results

1

Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis.

McKinzie CJ, Goralski JL, Noah TL, Retsch-Bogart GZ, Prieur MB. McKinzie CJ, et al. J Cyst Fibros. 2017 Jul;16(4):525-527. doi: 10.1016/j.jcf.2017.05.008. Epub 2017 Jun 8. J Cyst Fibros. 2017. PMID: 28602538 Free article.

2

Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding.

Trimble A, McKinzie C, Terrell M, Stringer E, Esther CR Jr. Trimble A, et al. J Cyst Fibros. 2018 Nov;17(6):779-782. doi: 10.1016/j.jcf.2018.05.009. Epub 2018 Jun 1. J Cyst Fibros. 2018. PMID: 29866531 Free PMC article.

3

Use of telavancin in adolescent patients with cystic fibrosis and prior intolerance to vancomycin: A case series.

Bernstein AT, Leigh MW, Goralski JL, Esther CR Jr, McKinzie CJ. Bernstein AT, et al. Among authors: mckinzie cj. J Cyst Fibros. 2018 Nov;17(6):e48-e50. doi: 10.1016/j.jcf.2018.08.003. Epub 2018 Aug 28. J Cyst Fibros. 2018. PMID: 30170755 Free article.

4

Use of inhaled imipenem/cilastatin in pediatric patients with cystic fibrosis: A case series.

Jones LA, Doucette L, Dellon EP, Esther CR, McKinzie CJ. Jones LA, et al. Among authors: mckinzie cj. J Cyst Fibros. 2019 Jul;18(4):e42-e44. doi: 10.1016/j.jcf.2019.04.017. Epub 2019 May 3. J Cyst Fibros. 2019. PMID: 31060800 Free PMC article.

5

Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis.

McKinzie CJ, Doligalski CT, Lobritto SJ, Coakley RD, Gower WA. McKinzie CJ, et al. J Cyst Fibros. 2022 Mar;21(2):227-229. doi: 10.1016/j.jcf.2021.07.017. Epub 2021 Aug 9. J Cyst Fibros. 2022. PMID: 34384711 Free article. No abstract available.

6

Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients.

Doligalski CT, McKinzie CJ, Yang A, Lobo LJ, Coakley R. Doligalski CT, et al. Among authors: mckinzie cj. Pharmacotherapy. 2022 Jul;42(7):580-584. doi: 10.1002/phar.2710. Epub 2022 Jun 21. Pharmacotherapy. 2022. PMID: 35689451

7

Changes in fecal elastase-1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis.

Stephenson KG, Lingle AJ, Baumberger KA, Dellon EP, Esther CR Jr, Meier EM, Oermann CM, Shenoy VK, Smith NR, Wimmer NS, Duehlmeyer SR, Kam CW, McKinzie CJ, Poisson MO, Elson EC. Stephenson KG, et al. Among authors: mckinzie cj. J Cyst Fibros. 2023 Nov;22(6):996-1001. doi: 10.1016/j.jcf.2023.09.005. Epub 2023 Sep 26. J Cyst Fibros. 2023. PMID: 37758535

8

Elevated creatine phosphokinase and rhabdomyolysis associated with elexacaftor/tezacaftor/ivacaftor use in cystic fibrosis.

McKinzie CJ, Kam CW, Jones MC, Gifford LB, Loughlin CE, Noah TL, Shenoy VK, Dellon EP. McKinzie CJ, et al. Pediatr Pulmonol. 2024 Mar 22. doi: 10.1002/ppul.26980. Online ahead of print. Pediatr Pulmonol. 2024. PMID: 38517044 No abstract available.

9

Continuous vancomycin in a pediatric cystic fibrosis patient.

McKinzie CJ, Esther CR, Vece TJ. McKinzie CJ, et al. Pediatr Pulmonol. 2018 Jan;53(1):E4-E5. doi: 10.1002/ppul.23844. Epub 2017 Nov 29. Pediatr Pulmonol. 2018. PMID: 29193836

10

Novel therapies for treatment of resistant and refractory nontuberculous mycobacterial infections in patients with cystic fibrosis.

Laudone TW, Garner L, Kam CW, Esther CR Jr, McKinzie CJ. Laudone TW, et al. Among authors: mckinzie cj. Pediatr Pulmonol. 2021 Feb;56 Suppl 1:S55-S68. doi: 10.1002/ppul.24939. Pediatr Pulmonol. 2021. PMID: 32609433 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

29 results

Search Page